Healthcare Sales & Marketing Network News: tumor necrosis factor

Searching News Database: tumor necrosis factor

HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Oct 2021
FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Nov 2019
Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Biopharmaceuticals Generics

HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch

HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Jun 2014
Solstice Biologics Appoints Dr. Lou Tartaglia as President, Chief Executive Officer; John Borgeson Joins as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 23 Aug 2013
ChemoCentryx Announces GlaxoSmithKline's Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 May 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Biopharmaceuticals

HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA

HSMN NewsFeed - 25 Mar 2013
XELJANZ(R) (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology

HSMN NewsFeed - 27 Jul 2012
Genentech Reports Second Positive Study of ACTEMRA(R) Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
ORENCIA(R) (abatacept) Demonstrates Comparable Efficacy to Humira(R) (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Biopharmaceuticals

HSMN NewsFeed - 3 May 2012
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
Biopharmaceuticals

HSMN NewsFeed - 2 Mar 2012
Genentech’s ACTEMRA(R) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
Biopharmaceuticals

HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2011
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Biopharmaceuticals Litigation

HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 26 Oct 2009
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Oct 2009
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Aug 2009
Updated ORENCIA(R) (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals

HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals

HSMN NewsFeed - 19 Nov 2008
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Nov 2008
TNFerade(TM) Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2008
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals

HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals

HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals

HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology

HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Apr 2008
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Biopharmaceuticals

HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 27 Feb 2008
FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jan 2008
New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective in Treating Psoriasis in Children and Adolescents
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2008
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
Biopharmaceuticals

HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology

HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing

HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution

HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine

HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Nov 2007
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals

HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals

HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Aug 2007
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA

HSMN NewsFeed - 22 May 2007
New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 7 May 2007
Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation

HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals

HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology

HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 12 Feb 2007
Targeted Genetics Provides Inflammatory Arthritis Clinical Trial Update
Biopharmaceuticals

HSMN NewsFeed - 2 Feb 2007
Psoriasis Patients Show Significant Improvement in Symptoms with Abbott's HUMIRA(R) in New Phase III Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 26 Jan 2007
GenVec Announces First Patient Treated with TNFerade(TM) for Head and Neck Cancer at University of Chicago
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jan 2007
GenVec Receives Clearance From FDA for EUS Administration of TNFerade(TM)
Biopharmaceuticals Oncology FDA Drug Delivery

HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology

HSMN NewsFeed - 22 Dec 2006
UCB Announces Positive Results From Two New Phase III Studies in Rheumatoid Arthritis and Provides Update on the Status of US Approval for CIMZIATM in the Treatment of Crohn's Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2006
GenVec Announces Efficacy Update in Phase II/III Clinical Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
GenVec Announces Completion of Interim Safety Data Analysis for Phase II/III Trial with TNFerade(TM) in Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2006
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2006
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 26 Oct 2006
Abbott's HUMIRA(R) (Adalimumab) Granted FDA Priority Review for the Treatment of Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 23 Oct 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jun 2006
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 22 Jun 2006
Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the European Rheumatology Meeting
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology

Return to NewsFeed

Additional items found! 135

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 135 additional stories matching:
tumor necrosis factor
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.